Coldstream Capital Management Inc. trimmed its position in Icon Plc (NASDAQ:ICLR) by 32.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,503 shares of the medical research company’s stock after selling 1,198 shares during the quarter. Coldstream Capital Management Inc.’s holdings in Icon were worth $342,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. CWM LLC lifted its stake in Icon by 211.8% in the fourth quarter. CWM LLC now owns 212 shares of the medical research company’s stock valued at $27,000 after buying an additional 144 shares during the period. Truehand Inc acquired a new stake in shares of Icon during the fourth quarter worth about $54,000. Benjamin F. Edwards & Company Inc. raised its position in shares of Icon by 36.6% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock worth $56,000 after purchasing an additional 116 shares during the period. Ellis Investment Partners LLC acquired a new stake in shares of Icon during the first quarter worth about $59,000. Finally, NumerixS Investment Technologies Inc acquired a new stake in shares of Icon during the fourth quarter worth about $64,000. Institutional investors and hedge funds own 85.73% of the company’s stock.
ICLR traded up $2.28 during trading on Friday, hitting $153.97. The stock had a trading volume of 321,886 shares, compared to its average volume of 293,301. The stock has a 50 day simple moving average of $142.29. The company has a market capitalization of $8.31 billion, a price-to-earnings ratio of 24.48, a price-to-earnings-growth ratio of 2.06 and a beta of 0.55. Icon Plc has a one year low of $118.10 and a one year high of $155.33. The company has a current ratio of 2.02, a quick ratio of 2.02 and a debt-to-equity ratio of 0.30.
A number of equities research analysts have recently commented on the company. Zacks Investment Research raised Icon from a “hold” rating to a “buy” rating and set a $155.00 price target on the stock in a research report on Friday, May 17th. BidaskClub lowered Icon from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 23rd. Barclays reissued a “hold” rating and issued a $154.00 target price on shares of Icon in a research report on Wednesday, April 17th. Mizuho lifted their target price on Icon from $154.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, June 11th. Finally, ValuEngine lowered Icon from a “buy” rating to a “hold” rating in a research report on Tuesday, April 16th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $156.63.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: Intrinsic Value
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.